

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

PW MEDTECH GROUP LIMITED

普华和顺集团公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1358)

DISCLOSEABLE TRANSACTION EXTENSION OF LOAN

EXTENSION OF LOAN

On April 23, 2026, the Lender and the Borrower entered into the Supplemental Loan Agreement to extend the maturity date of the Loan from April 23, 2026 to April 23, 2028.

IMPLICATIONS UNDER THE LISTING RULES

This announcement is made pursuant to Rule 14.36 of the Listing Rules, as the entering into of the Supplemental Loan Agreement constitutes a variation to the terms and conditions of the Loan Agreement which was previously announced by the Company on April 20, 2023.

As one or more of the applicable percentage ratios (as calculated under Rule 14.07 of the Listing Rules) in respect of the Supplemental Loan Agreement and the Loan is more than 5% but all less than 25%, the provision of the Loan remains a discloseable transaction of the Company and is subject to the reporting and announcement requirements set out in Chapter 14 of the Listing Rules.

INTRODUCTION

Reference is made to the announcement of the Company dated April 20, 2023 in relation to the Loan Agreement between the Lender (an indirect wholly-owned subsidiary of the Company) and the Borrower. Pursuant to the Loan Agreement, the Lender provided a loan in the principal amount of RMB180 million to the Borrower, and the Borrower shall repay the interests on a half-yearly basis and the outstanding principal amount in full before April 23, 2026.

EXTENSION OF LOAN

On April 23, 2026, the Lender and the Borrower entered into the Supplemental Loan Agreement to extend the maturity date of the Loan from April 23, 2026 to April 23, 2028.

The principal terms and conditions of the Loan Agreement as amended by the Supplemental Loan Agreement are set out below.

Date of the Supplemental Loan Agreement : April 23, 2026

Parties : (a) the Borrower; and
(b) the Lender (an indirect wholly-owned subsidiary of the Company)

To the best of the Directors' knowledge, information and belief having made all reasonable enquiries, each of the Borrower and its respective ultimate beneficial owners is a third party independent of the Company and its connected persons.

Principal of the Loan : RMB180 million

Term : From the date of drawdown of the Loan to April 23, 2028

Interest rate : 4.5% per annum during the period from April 24, 2026 to April 23, 2028

Permitted use of the Loan : The Borrower shall use the principal of the Loan for working capital, including but not limited to payment to its suppliers, purchase of raw material and equipment, payment of employee salary and loan repayment.

Repayment : The Borrower shall repay the interests on a half-yearly basis and the outstanding principal amount in full before the expiry of the loan term.

The terms of the Loan Agreement as amended by the Supplemental Loan Agreement, including the interest rate and the extended term of the Loan, were agreed by the Lender and the Borrower after arm's length negotiations and having taken into account prevailing market conditions.

Funding for the principal of the Loan

The principal of the Loan will be financed by the Group's available internal resources.

Collateral

The Loan will be secured by the real properties owned by the Borrower located in Beijing, the PRC with a gross floor area of 36,836.33 m² (the “**Properties**”) for the repayment obligations of the Borrower under the Loan Agreement. According to the valuation report issued by Zhong Qi Ying (Beijing) Asset Appraisal Co., Ltd. (中企盈(北京)資產評估有限公司), the value of the Properties was RMB245,805,000 as of December 31, 2025. Without prior written consent by the Lender, the Borrower shall not dispose of the Properties within the term of the Loan.

INFORMATION ON THE LENDER AND THE GROUP

The Lender is an indirect wholly-owned subsidiary of the Company. The Lender is principally engaged in the development, manufacturing and sale of advanced infusion set, intravenous cannula products, insulin needles etc..

The Company is an exempted company incorporated under the laws of the Cayman Islands with limited liability on May 13, 2011. The principal business activity of the Company is investment holding. The Group is principally engaged in the R&D, manufacturing and sale of (i) advanced infusion set, intravenous cannula products, insulin needles etc., (ii) blood purification medical devices, and (iii) animal-derived regenerative medical biomaterials and human tissue repair alternative products in the PRC.

INFORMATION ON THE BORROWER

The Borrower is principally engaged in the investment, construction, operation and management of medical device industrial park and the investment and management of medical product projects. The Borrower was ultimately owned by Liao Wanfeng (廖晚鳳) as to 97.5% and Ran Nianmo (冉年模) as to 2.5%.

REASONS FOR AND BENEFITS OF ENTERING INTO THE SUPPLEMENTAL LOAN AGREEMENT

The terms of the Supplemental Loan Agreement, including the interest rate and the extended term of the Loan, were agreed by the Lender and the Borrower after arm’s length negotiations and on normal commercial terms. The Company has conducted due diligence procedures to re-assess the Borrower’s financial position, the punctual records of interest payment by the Borrower and the value of the Properties before entering into the Supplemental Loan Agreement and was not aware of any event that may lead the Company to doubt the credibility and repayment ability of the Borrower. Taking into account the results of due diligence on the credibility and repayment ability of the Borrower and the stable interest income expected to be generated from the Loan with extended term, the Directors are of the opinion that the terms of the Supplemental Loan Agreement are fair and reasonable and in the interest of the Company and its Shareholders as a whole.

IMPLICATIONS UNDER THE LISTING RULES

This announcement is made pursuant to Rule 14.36 of the Listing Rules, as the entering into of the Supplemental Loan Agreement constitutes a variation to the terms and conditions of the Loan Agreement which was previously announced by the Company on April 20, 2023.

As one or more of the applicable percentage ratios (as calculated under Rule 14.07 of the Listing Rules) in respect of the Supplemental Loan Agreement and the Loan is more than 5% but all less than 25%, the provision of the Loan remains a discloseable transaction of the Company and is subject to the reporting and announcement requirements set out in Chapter 14 of the Listing Rules.

DEFINITIONS

In this announcement, the following expressions have the meanings set out below unless the context otherwise requires:

“Board”	the board of Directors
“Borrower”	Beijing Tianxia Pule Medical Investment Co., Ltd.* (北京天下普樂醫療投資有限公司), a limited liability company established under the laws of the PRC on September 22, 2011
“Company”	PW Medtech Group Limited (普華和順集團公司), an exempted company incorporated under the laws of the Cayman Islands with limited liability on May 13, 2011, whose principal business activity is investment holding and the shares of which are listed on the Main Board of the Stock Exchange (Stock Code: 1358)
“connected person”	has the meaning ascribed thereto under the Listing Rules
“Director(s)”	the director(s) of the Company
“Group”	the Company and its subsidiaries
“Hong Kong”	the Hong Kong Special Administrative Region of the PRC
“Lender”	Beijing Fert Technology Co., Ltd.* (北京伏爾特技術有限公司), a limited liability company established under the laws of the PRC on September 23, 1997 and indirectly wholly owned by the Company
“Listing Rules”	the Rules Governing the Listing of Securities on the Stock Exchange (as amended from time to time)
“Loan”	the loan in the principal amount of RMB180 million provided by the Lender to the Borrower pursuant to the Loan Agreement

“Loan Agreement”	the loan agreement dated April 20, 2023 entered into between the Borrower and the Lender in relation to the provision of the Loan to the Borrower
“PRC”	the People’s Republic of China which, for the purpose of this announcement, except where the context requires otherwise, excludes Hong Kong, the Macau Special Administrative Region of the PRC and Taiwan
“RMB”	Renminbi, the lawful currency of the PRC
“Shareholder(s)”	shareholder(s) of the Company from time to time
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“Supplemental Loan Agreement”	the supplemental agreement dated April 23, 2026 entered into between the Borrower and the Lender in relation to the extension of the maturity date of the Loan
“%”	per cent

By Order of the Board
PW Medtech Group Limited
Yue’e ZHANG
Chairman

Beijing, the PRC, April 23, 2026

As at the date of this announcement, the Board comprises one executive Director, namely, Ms. Yue’e Zhang; two non-executive Directors, namely Mr. Jiang Liwei and Mr. Lin Junshan; and three independent non-executive Directors, namely, Mr. Wang Xiaogang, Mr. Chen Geng and Ms. Wang Fengli.

* *For identification purpose only*